Alcoholic Liver Disease
40
9
12
19
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.5%
1 terminated out of 40 trials
95.0%
+8.5% vs benchmark
15%
6 trials in Phase 3/4
5%
1 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (40)
Intra-Hepatic Microbiota in Alcoholic Hepatitis
Integrated Diagnostics for Early Diagnosis of Liver Disease
Ethanol Induces Skeletal Muscle Autophagy
Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone
Quantitative MRI for Non-invasive Assessment of Severity of Alcoholic Liver Disease (ALD)
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease
Alcoholic Liver Disease and the Gut Microbiome
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota
Integrated Approaches for Identifying Molecular Targets in Liver Disease
French National MICMAF Cohort
The Liver Care Trial
Gut Mycobiome Profile in Alcoholic Liver Disease.
Early Detection of Alcoholic Liver Disease
Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
Alcohol, Gut Leakiness, & Liver Disease
Study of Alcohol-related Liver Disease in Europe